Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 1
2005 2
2006 1
2007 2
2008 1
2010 1
2014 1
2017 1
2018 1
2019 1
2020 1
2021 2
2022 3
2023 6
2024 7
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Lincoff AM, et al. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. N Engl J Med. 2023. PMID: 37952131 Clinical Trial.
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Bhatt DL, et al. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415628 Clinical Trial.
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, Lingvay I, Colhoun HM, Plutzky J, Kosiborod MN, Hovingh GK, Hardt-Lindberg S, Frenkel O, Weeke PE, Rasmussen S, Goudev A, Lang CC, Urina-Triana M, Pietilä M, Lincoff AM; SELECT Trial Investigators. Deanfield J, et al. Lancet. 2024 Aug 24;404(10454):773-786. doi: 10.1016/S0140-6736(24)01498-3. Lancet. 2024. PMID: 39181597 Free article. Clinical Trial.
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
Burger PM, Bhatt DL, Dorresteijn JAN, Koudstaal S, Mosterd A, Martens FMAC, Steg PG, Visseren FLJ; REDUCE-IT Investigators. Burger PM, et al. Among authors: martens fmac. Eur Heart J Cardiovasc Pharmacother. 2024 Oct 4;10(6):488-499. doi: 10.1093/ehjcvp/pvae030. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38678009 Free PMC article. Clinical Trial.
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial.
Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, Dunbar RL, Ketchum SB, Tardif JC, Martens FMAC, Ballantyne CM, Szarek M, Mason RP; REDUCE‐IT Investigators. Aggarwal R, et al. Among authors: martens fmac. J Am Heart Assoc. 2025 Mar 4;14(5):e038656. doi: 10.1161/JAHA.124.038656. Epub 2025 Feb 19. J Am Heart Assoc. 2025. PMID: 39968782 Free PMC article. Clinical Trial.
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial.
Koren MJ, Descamps O, Hata Y, Hengeveld EM, Hovingh GK, Ikonomidis I, Radu Juul Jensen MD, Langbakke IH, Martens FMAC, Søndergaard AL, Witkowski A, Koenig W. Koren MJ, et al. Among authors: martens fmac. Lancet Diabetes Endocrinol. 2024 Mar;12(3):174-183. doi: 10.1016/S2213-8587(23)00325-X. Epub 2024 Feb 1. Lancet Diabetes Endocrinol. 2024. PMID: 38310920 Clinical Trial.
Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT.
Gurevitz C, Bhatt DL, Giugliano RP, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Lira Pineda A, Doyle RT Jr, Giugliano G, Mason RP, Tardif JC, Martens FMAC, Ballantyne CM, Budoff MJ, Gibson CM. Gurevitz C, et al. Among authors: martens fmac. Eur J Prev Cardiol. 2025 Sep 22:zwaf602. doi: 10.1093/eurjpc/zwaf602. Online ahead of print. Eur J Prev Cardiol. 2025. PMID: 40982548
[The PROMINENT trial: swan song of the fibrates].
van Sloten TT, Martens FMAC, Visseren FLJ. van Sloten TT, et al. Among authors: martens fmac. Ned Tijdschr Geneeskd. 2023 Apr 5;167:D7528. Ned Tijdschr Geneeskd. 2023. PMID: 37022121 Dutch.
Coronary CT angiography evaluation with artificial intelligence for individualized medical treatment of atherosclerosis: a Consensus Statement from the QCI Study Group.
Schulze K, Stantien AM, Williams MC, Vassiliou VS, Giannopoulos AA, Nieman K, Maurovich-Horvat P, Tarkin JM, Vliegenthart R, Weir-McCall J, Mohamed M, Föllmer B, Biavati F, Stahl AC, Knape J, Balogh H, Galea N, Išgum I, Arbab-Zadeh A, Alkadhi H, Manka R, Wood DA, Nicol ED, Nurmohamed NS, Martens FMAC, Dey D, Newby DE, Dewey M. Schulze K, et al. Among authors: martens fmac. Nat Rev Cardiol. 2025 Aug 1. doi: 10.1038/s41569-025-01191-6. Online ahead of print. Nat Rev Cardiol. 2025. PMID: 40751112 Review.
39 results